These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7587057)

  • 1. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young.
    Kearns GL; Young RA
    Diagn Microbiol Infect Dis; 1995; 22(1-2):97-104. PubMed ID: 7587057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates.
    Kearns GL; Jacobs RF; Thomas BR; Darville TL; Trang JM
    J Pediatr; 1989 Mar; 114(3):461-7. PubMed ID: 2921690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn.
    Aujard Y; Brion F; Jacqz-Aigrain E; Kasse MC; Chretien P; Criqui C; Mathieu H
    Diagn Microbiol Infect Dis; 1989; 12(1):87-91. PubMed ID: 2653716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
    Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefotaxime in preterm infants.
    Gouyon JB; Pechinot A; Safran C; Chretien P; Sandre D; Kazmierczak A
    Dev Pharmacol Ther; 1990; 14(1):29-34. PubMed ID: 2311478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.
    Trang JM; Jacobs RF; Kearns GL; Brown AL; Wells TG; Underwood FL; Kluza RB
    Antimicrob Agents Chemother; 1985 Dec; 28(6):791-5. PubMed ID: 4083862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefotaxime and desacetylcefotaxime in neonates and children: a review of microbiologic, pharmacokinetic, and clinical experience.
    Jacobs RF; Kearns GL
    Diagn Microbiol Infect Dis; 1989; 12(1):93-9. PubMed ID: 2653717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefotaxime in dialysis patients.
    Andrassy K
    Diagn Microbiol Infect Dis; 1995; 22(1-2):85-7. PubMed ID: 7587055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefotaxime in healthy volunteers and patients.
    Patel KB; Nicolau DP; Nightingale CH; Quintiliani R
    Diagn Microbiol Infect Dis; 1995; 22(1-2):49-55. PubMed ID: 7587050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.
    Ahsman MJ; Wildschut ED; Tibboel D; Mathot RA
    Antimicrob Agents Chemother; 2010 May; 54(5):1734-41. PubMed ID: 20176908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections.
    Boccazzi A; Tonelli P; Bellosta C; Careddu P
    Diagn Microbiol Infect Dis; 1998 Dec; 32(4):265-72. PubMed ID: 9934543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of gender on the disposition of cefotaxime and desacetylcefotaxime.
    Guay DR; Matzke GR; Heim KL; Halstenson CE; Abraham PA; Keane WF
    Ther Drug Monit; 1987 Sep; 9(3):259-62. PubMed ID: 3672567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JA
    Ann Pharmacother; 1992 Mar; 26(3):341-3. PubMed ID: 1554953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
    Dulaney Lopez AM; Rodriguez JC; Lopez-Samblas AM; Estes KS
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of cefotaxime, desacetylcefotaxime, and the combination of the two.
    Friis H
    Diagn Microbiol Infect Dis; 1989; 12(1):67-72. PubMed ID: 2714074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.
    Fuchs PC; Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(1):81-5. PubMed ID: 2714075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of cefotaxime and its metabolite, desacetylcefotaxime, in rat: application of a pharmacokinetic-protein binding model.
    Hakim L; Bourne DW; Triggs EJ
    Xenobiotica; 1989 Jul; 19(7):743-54. PubMed ID: 2773510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase.
    Stratton CW; Kernodle DS; Eades SC; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(1):57-65. PubMed ID: 2785444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.